Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* With severe non-critical stage of COVID at the time of admission.~* Patients tested positive for SARS-CoV-2 confirmed by PCR (Polymerase Chain Reaction) or quick antigen test~* Within the first 12 days post appearance of symptoms~* With at least one of the following risk factors: Diabetes mellitus (DM), obesity (BMI\>30, hypertension, age \> 65 years.~* Respiratory rate 25-34/min and no signs of respiratory distress.~* With at least two of the following indicators of severity: SpO2 81-90%, PaFi 150-300 mmHg, FiO2\>60% , lung damage in thorax radiographic image =\> 25% as determined by RALE score (an equivalent to 2-4).~* Normal liver function (Considered up to a fivefold increase above the normal limits of hepatic transaminases)~* Signed informed consent~Exclusion Criteria:~* Pregnant or lactating women~* Patients already participating in another clinical study~* Oxygen saturation \< 70% (ambient)~* Clinical evidence of an infectious disease different from COVID at the time of admission~* Chronic kidney failure~* Coronary disease~* Glomerular filtration rate \< 30ml/min/1.73 m2 and known history of preexisting chronic renal failure (Chronic kidney disease stages 4-5)~* Known history of HCV, HBV and/or clinical signs of hepatic liver failure.~* Any type of cancer~* HIV and/or any anti retroviral treatment~* Inability to freely decide to participate~* Psychotropics treatment~* Erythromycin treatment~* Polydrug use (Defined as more than two addictions combined)~* With transplant background~* With any autoimmune disorder~* With known hypersensibility to maraviroc and/or favipiravir~* On invasive mechanical ventilation at the time of randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Currently used therapy (CT) only (Type: ACTIVE_COMPARATOR): Treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients: Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present.
- Maraviroc+CT (Type: EXPERIMENTAL): Maraviroc AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients.
- Favipiravir+CT (Type: EXPERIMENTAL): Favipiravir AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients.
- Maraviroc+Favipiravir+CT (Type: EXPERIMENTAL): Maraviroc AND Favipiravir AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients

Based on this trial design, predict the completion outcome and termination type (if applicable).